
Andreas Scorilas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8343178/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	BCL2Family of Apoptosis-Related Genes: Functions and Clinical Implications in Cancer. Critical Reviews in Clinical Laboratory Sciences, 2006, 43, 1-67.	2.7	214
2	Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. British Journal of Cancer, 2001, 84, 1488-1496.	2.9	210
3	Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma. Journal of Clinical Oncology, 2003, 21, 1035-1043.	0.8	188
4	Genomic Organization of the Human Kallikrein Gene Family on Chromosome 19q13.3–q13.4. Biochemical and Biophysical Research Communications, 2000, 276, 125-133.	1.0	183
5	The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias. Advances in Hematology, 2012, 2012, 1-15.	0.6	183
6	Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. Clinical Cancer Research, 2016, 22, 704-713.	3.2	173
7	A new tumor suppressor role for the Notch pathway in bladder cancer. Nature Medicine, 2014, 20, 1199-1205.	15.2	160
8	The miR-17-92 Cluster is Over Expressed in and Has an Oncogenic Effect on Renal Cell Carcinoma. Journal of Urology, 2010, 183, 743-751.	0.2	149
9	Lactate Dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. Molecular Cancer, 2014, 13, 101.	7.9	141
10	Structure and biological properties of the copper(II) complex with the quinolone antibacterial drug N-propyl-norfloxacin and 2,2′-bipyridine. Journal of Inorganic Biochemistry, 2007, 101, 64-73.	1.5	137
11	Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Research, 2003, 63, 2223-7.	0.4	126
12	A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biological Chemistry, 2006, 387, 637-41.	1.2	123
13	The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Research, 2003, 63, 807-11.	0.4	123
14	Hepsin is Highly Over Expressed in and a New Candidate for a Prognostic Indicator in Prostate Cancer. Journal of Urology, 2004, 171, 187-191.	0.2	117
15	Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. British Journal of Cancer, 2001, 84, 643-650.	2.9	116
16	SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions. Science of the Total Environment, 2022, 804, 150151.	3.9	116
17	The PRMT1 gene expression pattern in colon cancer. British Journal of Cancer, 2008, 99, 2094-2099.	2.9	114
18	Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Research, 2003, 63, 3958-65.	0.4	109

#	Article	IF	CITATIONS
19	The Clinical Utility of miR-21 as a Diagnostic and Prognostic Marker for Renal Cell Carcinoma. Journal of Molecular Diagnostics, 2012, 14, 385-392.	1.2	106
20	Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends in Molecular Medicine, 2022, 28, 542-554.	3.5	104
21	The Combination of Human Clandular Kallikrein and Free Prostate-specific Antigen (PSA) Enhances Discrimination Between Prostate Cancer and Benign Prostatic Hyperplasia in Patients with Moderately Increased Total PSA. Clinical Chemistry, 1999, 45, 1960-1966.	1.5	103
22	Molecular Cloning of the Human Kallikrein 15 Gene (KLK15). Journal of Biological Chemistry, 2001, 276, 53-61.	1.6	103
23	Serum Human Glandular Kallikrein-2 Protease Levels Predict the Presence of Prostate Cancer Among Men With Elevated Prostate-Specific Antigen. Journal of Clinical Oncology, 2000, 18, 1036-1036.	0.8	99
24	Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology, 2000, 56, 527-532.	0.5	99
25	<i>Phosphatidylinositol 3′-Kinase Catalytic Subunit α</i> Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma. Clinical Cancer Research, 2009, 15, 5724-5732.	3.2	99
26	The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clinical Cancer Research, 2001, 7, 806-11.	3.2	98
27	Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clinical Cancer Research, 2001, 7, 2380-6.	3.2	95
28	Human kallikrein 10: a novel tumor marker for ovarian carcinoma?. Clinica Chimica Acta, 2001, 306, 111-118.	0.5	94
29	The lysineâ€specific methyltransferase <scp>KMT</scp> 2C/ <scp>MLL</scp> 3 regulates <scp>DNA</scp> repair components in cancer. EMBO Reports, 2019, 20, .	2.0	93
30	The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. British Journal of Cancer, 2013, 108, 2573-2581.	2.9	90
31	Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer. Annals of Translational Medicine, 2018, 6, 241-241.	0.7	90
32	Molecular Cloning, Physical Mapping, and Expression Analysis of a Novel Gene, BCL2L12, Encoding a Proline-Rich Protein with a Highly Conserved BH2 Domain of the Bcl-2 Family. Genomics, 2001, 72, 217-221.	1.3	89
33	Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectives. TrAC - Trends in Analytical Chemistry, 2021, 134, 116125.	5.8	88
34	The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family — genomic characterization, mapping, tissue expression and hormonal regulation. Gene, 2000, 254, 119-128.	1.0	87
35	Apoptosis-related BCL2-family Members: Key Players in Chemotherapy. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 353-374.	0.9	85
36	Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. British Journal of Cancer, 2003, 88, 1101-1104.	2.9	84

#	Article	IF	CITATIONS
37	Human Kallikrein Gene 5 (KLK5) Expression by Quantitative PCR: An Independent Indicator of Poor Prognosis in Breast Cancer. Clinical Chemistry, 2002, 48, 1241-1250.	1.5	82
38	The emergence of drug resistance to targeted cancer therapies: Clinical evidence. Drug Resistance Updates, 2019, 47, 100646.	6.5	81
39	Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biological Chemistry, 2012, 393, 301-317.	1.2	79
40	Differential Protein Expressions in Renal Cell Carcinoma: New Biomarker Discovery by Mass Spectrometry. Journal of Proteome Research, 2009, 8, 3797-3807.	1.8	78
41	Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clinical Cancer Research, 2001, 7, 2372-9.	3.2	78
42	Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biological Chemistry, 2010, 391, 505-511.	1.2	75
43	Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1877-1891.	1.4	74
44	RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2014, 20, 2933-2946.	3.2	74
45	Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker. Journal of Clinical Oncology, 2004, 22, 678-685.	0.8	73
46	Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Research, 2001, 61, 7811-8.	0.4	72
47	Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. British Journal of Cancer, 2002, 87, 763-771.	2.9	71
48	Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Research, 2003, 63, 2771-4.	0.4	71
49	Effects of Long-term Androgen Administration on Breast Tissue of Female-to-Male Transsexuals. Journal of Histochemistry and Cytochemistry, 2006, 54, 905-910.	1.3	70
50	Streptavidin-Polyvinylamine Conjugates Labeled with a Europium Chelate: Applications in Immunoassay, Immunohistochemistry, and Microarrays. Clinical Chemistry, 2000, 46, 1450-1455.	1.5	69
51	Prognostic Value of the Human Kallikrein Gene 15 Expression in Ovarian Cancer. Journal of Clinical Oncology, 2003, 21, 3119-3126.	0.8	69
52	A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to Chemotherapy. Clinical Cancer Research, 2007, 13, 6984-6992.	3.2	69
53	Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clinical Biochemistry, 2003, 36, 135-143.	0.8	68
54	Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer Letters, 2004, 205, 97-106.	3.2	68

#	Article	IF	CITATIONS
55	Low Expression of miR-126 Is a Prognostic Marker for Metastatic Clear Cell Renal Cell Carcinoma. American Journal of Pathology, 2015, 185, 693-703.	1.9	68
56	Detection of Human Kallikrein 4 in Healthy and Cancerous Prostatic Tissues by Immunofluorometry and Immunohistochemistry. Clinical Chemistry, 2002, 48, 1232-1240.	1.5	67
57	B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecologic Oncology, 2007, 106, 334-341.	0.6	67
58	Clinical evaluation of PRMT1 gene expression in breast cancer. Tumor Biology, 2011, 32, 575-582.	0.8	67
59	Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment. Carcinogenesis, 2015, 36, 528-537.	1.3	67
60	Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Oncotarget, 2015, 6, 39088-39097.	0.8	67
61	Third-Generation Sequencing: The Spearhead towards the Radical Transformation of Modern Genomics. Life, 2022, 12, 30.	1.1	67
62	The Chromatin Remodeling Gene ARID1A Is a New Prognostic Marker in Clear Cell Renal Cell Carcinoma. American Journal of Pathology, 2013, 182, 1163-1170.	1.9	66
63	Genomic Organization, Physical Mapping, and Expression Analysis of the Human Protein Arginine Methyltransferase 1 Gene. Biochemical and Biophysical Research Communications, 2000, 278, 349-359.	1.0	65
64	Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thrombosis and Haemostasis, 2004, 91, 180-186.	1.8	65
65	Downregulation and Prognostic Performance of MicroRNA 224 Expression in Prostate Cancer. Clinical Chemistry, 2013, 59, 261-269.	1.5	65
66	Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate, 2002, 51, 126-132.	1.2	64
67	Genomic Organization, Mapping, Tissue Expression, and Hormonal Regulation of Trypsin-like Serine Protease (TLSP PRSS20), a New Member of the Human Kallikrein Gene Family. Genomics, 2000, 63, 88-96.	1.3	62
68	Steroid Hormone Regulation and Prognostic Value of the Human Kallikrein Gene 14 in Ovarian Cancer. American Journal of Clinical Pathology, 2003, 119, 346-355.	0.4	62
69	Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer. Clinical Cancer Research, 2006, 12, 1487-1493.	3.2	60
70	Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Letters, 2007, 247, 48-55.	3.2	60
71	The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression. International Journal of Oncology, 2013, 42, 1770-1777.	1.4	60
72	Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 in Benign Prostatic Hyperplasia and Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 694-699.	1.8	59

#	Article	IF	CITATIONS
73	Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate, 2003, 56, 287-292.	1.2	59
74	Human kallikrein gene 13 (KLK13) expression by quantitative RT–PCR: an independent indicator of favourable prognosis in breast cancer. British Journal of Cancer, 2002, 86, 1457-1464.	2.9	58
75	Human Tissue Kallikreins: From Gene Structure to Function and Clinical Applications. Advances in Clinical Chemistry, 2005, 39, 11-79.	1.8	58
76	TNF-alpha expression and apoptosis-regulating proteins in oral lichen planus: a comparative immunohistochemical evaluation. Journal of Oral Pathology and Medicine, 2000, 29, 370-375.	1.4	56
77	Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. International Journal of Cancer, 2003, 106, 605-610.	2.3	56
78	The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. British Journal of Cancer, 2009, 100, 1659-1665.	2.9	55
79	Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncology, 2010, 6, 269-285.	1.1	55
80	miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma. Journal of Molecular Diagnostics, 2015, 17, 136-144.	1.2	55
81	Quantitative Analysis of Kallikrein 15 Gene Expression in Prostate Tissue. Journal of Urology, 2003, 169, 361-364.	0.2	53
82	Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. British Journal of Cancer, 2014, 110, 1250-1259.	2.9	52
83	Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naA¯ve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Medicine, 2021, 19, 208.	2.3	52
84	The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner. Cancer Chemotherapy and Pharmacology, 2007, 61, 251-265.	1.1	50
85	Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. British Journal of Cancer, 2010, 102, 1384-1390.	2.9	50
86	Quantitative analysis of the mRNA expression levels of BCL2 and BAX genes in human osteoarthritis and normal articular cartilage: An investigation into their differential expression. Molecular Medicine Reports, 2015, 12, 4514-4521.	1.1	50
87	Micro <scp>RNA</scp> â€194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma. Cancer Medicine, 2016, 5, 656-664.	1.3	50
88	Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. Urology, 2002, 60, 714-718.	0.5	49
89	Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. Clinical Biochemistry, 2002, 35, 225-231.	0.8	49
90	Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study. Laboratory Investigation, 2012, 92, 46-56.	1.7	48

#	Article	IF	CITATIONS
91	Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer. Clinical Biochemistry, 2013, 46, 1453-1461.	0.8	48
92	The oncomiR miR-197 is a novel prognostic indicator for non-small cell lung cancer patients. British Journal of Cancer, 2015, 112, 1527-1535.	2.9	48
93	JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. European Journal of Cancer, 2020, 126, 125-135.	1.3	48
94	Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. Clinical Biochemistry, 2004, 37, 823-829.	0.8	47
95	Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer. International Journal of Molecular Sciences, 2019, 20, 1291.	1.8	47
96	Expression of Gelatinase-A (MMP-2) in Human Colon Cancer and Normal Colon Mucosa. Tumor Biology, 2001, 22, 383-389.	0.8	46
97	The Prognostic Value of the Human Kallikrein Gene 9 (KLK9) in Breast Cancer. Breast Cancer Research and Treatment, 2003, 78, 149-158.	1.1	46
98	Immunofluorometric Quantification of Human Kallikrein 5 Expression in Ovarian Cancer Cytosols and Its Association with Unfavorable Patient Prognosis. Tumor Biology, 2003, 24, 299-309.	0.8	45
99	Polyadenylate polymerase modulations in human epithelioid cervix and breast cancer cell lines, treated with etoposide or cordycepin, follow cell cycle rather than apoptosis induction. Biological Chemistry, 2005, 386, 471-480.	1.2	44
100	Unfavorable Prognostic Value of Human Kallikrein 7 Quantified by ELISA in Ovarian Cancer Cytosols. Clinical Chemistry, 2006, 52, 1879-1886.	1.5	44
101	High miR-96 levels in colorectal adenocarcinoma predict poor prognosis, particularly in patients without distant metastasis at the time of initial diagnosis. Tumor Biology, 2016, 37, 11815-11824.	0.8	44
102	Cisplatin-Induced Apoptosis in HL-60 Human Promyelocytic Leukemia Cells. Annals of the New York Academy of Sciences, 2003, 1010, 153-158.	1.8	43
103	Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Clinical Biochemistry, 2004, 37, 230-237.	0.8	43
104	Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. British Journal of Cancer, 2007, 96, 362-372.	2.9	43
105	The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. British Journal of Cancer, 2002, 87, 1294-1300.	2.9	42
106	Determination of Cathepsin B Expression May Offer Additional Prognostic Information for Ovarian Cancer Patients. Biological Chemistry, 2002, 383, 1297-303.	1.2	42
107	Alterations in mRNA Expression of Apoptosis-Related Genes BCL2, BAX, FAS, Caspase-3, and the Novel Member BCL2L12 after Treatment of Human Leukemic Cell Line HL60 with the Antineoplastic Agent Etoposide. Annals of the New York Academy of Sciences, 2006, 1090, 89-97.	1.8	42
108	Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions. Drug Resistance Updates, 2020, 48, 100662.	6.5	42

#	Article	IF	CITATIONS
109	Circular RNAs: A New Piece in the Colorectal Cancer Puzzle. Cancers, 2020, 12, 2464.	1.7	42
110	Circular RNAs: Emerging Regulators of the Major Signaling Pathways Involved in Cancer Progression. Cancers, 2021, 13, 2744.	1.7	42
111	The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Research, 2003, 63, 6543-6.	0.4	42
112	Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. Urology, 2003, 61, 1042-1046.	0.5	41
113	Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients. British Journal of Cancer, 2018, 119, 1477-1486.	2.9	41
114	miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers. Expert Review of Molecular Diagnostics, 2018, 18, 963-979.	1.5	41
115	Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis. Oncotarget, 2016, 7, 54415-54429.	0.8	41
116	Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. British Journal of Cancer, 2002, 87, 1287-1293.	2.9	40
117	Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Prostate, 2003, 54, 220-229.	1.2	40
118	Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clinica Chimica Acta, 2005, 357, 190-195.	0.5	40
119	Quantitative expression analysis and prognostic significance of the novel apoptosis-related gene <i>BCL2L12</i> in colon cancer. Biological Chemistry, 2008, 389, 1467-1475.	1.2	40
120	miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma. Molecular Diagnosis and Therapy, 2017, 21, 453-464.	1.6	40
121	Evolution of the Plasma and Tissue Kallikreins, and Their Alternative Splicing Isoforms. PLoS ONE, 2013, 8, e68074.	1.1	40
122	BCL2L12 is a Novel Biomarker for the Prediction of Short-Term Relapse in Nasopharyngeal Carcinoma. Molecular Medicine, 2011, 17, 163-171.	1.9	39
123	The Novel Member of the <i>BCL2</i> Gene Family, <i>BCL2L12</i> , Is Substantially Elevated in Chronic Lymphocytic Leukemia Patients, Supporting Its Value As a Significant Biomarker. Oncologist, 2011, 16, 1280-1291.	1.9	39
124	Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1217-27.	1.4	39
125	Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis. British Journal of Cancer, 1999, 81, 1385-1391.	2.9	38
126	Breast Cancer Cells Response to the Antineoplastic Agents Cisplatin, Carboplatin, and Doxorubicin at the mRNA Expression Levels of Distinct Apoptosis-Related Genes, Including the New Member, BCL2L12. Annals of the New York Academy of Sciences, 2007, 1095, 35-44.	1.8	38

#	Article	IF	CITATIONS
127	Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. Radiology and Oncology, 2013, 47, 319-329.	0.6	38
128	miR-224 overexpression is a strong and independent prognosticator of short-term relapse and poor overall survival in colorectal adenocarcinoma. International Journal of Oncology, 2015, 46, 849-859.	1.4	38
129	Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. Thrombosis and Haemostasis, 2003, 89, 1081-1088.	1.8	37
130	Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer. Clinical Biochemistry, 2008, 41, 1140-1149.	0.8	37
131	Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thrombosis and Haemostasis, 2009, 101, 741-747.	1.8	37
132	Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol. Tumor Biology, 2012, 33, 865-875.	0.8	37
133	Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: Mechanistic and clinical aspects. Thrombosis and Haemostasis, 2013, 110, 450-457.	1.8	37
134	Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Annals of Oncology, 2011, 22, 877-883.	0.6	36
135	Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies. Expert Opinion on Therapeutic Targets, 2016, 20, 801-818.	1.5	36
136	The role of circular RNAs in therapy resistance of patients with solid tumors. Personalized Medicine, 2020, 17, 469-490.	0.8	35
137	Human Glandular Kallikrein in Breast Milk, Amniotic Fluid, and Breast Cyst Fluid. Clinical Chemistry, 1999, 45, 1774-1780.	1.5	34
138	Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Biological Chemistry, 2006, 387, 1081-6.	1.2	34
139	Molecular Profile of the <i>BCL2</i> Family of the Apoptosis Related Genes in Breast Cancer Cells after Treatment with Cytotoxic/Cytostatic Drugs. Connective Tissue Research, 2008, 49, 261-264.	1.1	34
140	Molecular analysis and prognostic impact of the novel apoptotic gene BCL2L12 in gastric cancer. Biochemical and Biophysical Research Communications, 2010, 391, 214-218.	1.0	34
141	Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma. Tumor Biology, 2014, 35, 4673-4685.	0.8	34
142	mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biological Chemistry, 2004, 385, 1099-103.	1.2	33
143	Upregulated miR-16 expression is an independent indicator of relapse and poor overall survival of colorectal adenocarcinoma patients. Clinical Chemistry and Laboratory Medicine, 2017, 55, 737-747.	1.4	33
144	miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment. British Journal of Cancer, 2017, 117, 801-812.	2.9	33

#	Article	IF	CITATIONS
145	Natural Alkaloids Intervening the Insulin Pathway: New Hopes for Anti-Diabetic Agents?. Current Medicinal Chemistry, 2019, 26, 5982-6015.	1.2	33
146	Nature Promises New Anticancer Agents: Interplay with the Apoptosis-related BCL2 Gene Family. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 375-399.	0.9	33
147	Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. Clinical Chemistry, 2002, 48, 1241-50.	1.5	33
148	Polyvinylamine-streptavidin complexes labeled with a europium chelator: a universal detection reagent for solid-phase time resolved fluorometric applications. Clinical Biochemistry, 2000, 33, 345-350.	0.8	32
149	High BAX/BCL2 mRNA ratio predicts favorable prognosis in laryngeal squamous cell carcinoma, particularly in patients with negative lymph nodes at the time of diagnosis. Clinical Biochemistry, 2016, 49, 890-896.	0.8	32
150	MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis. Disease Markers, 2017, 2017, 1-10.	0.6	32
151	Prostate-Specific Antigen and Human Glandular Kallikrein 2 Are Markedly Elevated in Urine of Patients with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1558-1561.	1.8	31
152	The effect of the polyadenylation inhibitor cordycepin on human Molt-4 and Daudi leukaemia and lymphoma cell lines. Cancer Chemotherapy and Pharmacology, 2008, 61, 703-711.	1.1	31
153	Elevated expression of miR-24-3p is a potentially adverse prognostic factor in colorectal adenocarcinoma. Clinical Biochemistry, 2017, 50, 285-292.	0.8	31
154	Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. Life, 2020, 10, 214.	1.1	31
155	tRNA-Derived Fragments (tRFs) in Bladder Cancer: Increased 5′-tRF-LysCTT Results in Disease Early Progression and Patients' Poor Treatment Outcome. Cancers, 2020, 12, 3661.	1.7	31
156	MicroRNAs: Tiny Regulators of Gene Expression with Pivotal Roles in Normal B-Cell Development and B-Cell Chronic Lymphocytic Leukemia. Cancers, 2021, 13, 593.	1.7	31
157	Expression analysis of BCL2L12, a new member of apoptosis-related genes, in colon cancer. Biological Chemistry, 2004, 385, 779-83.	1.2	30
158	Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer. Tumor Biology, 2011, 32, 737-744.	0.8	30
159	Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer. Pathology Research and Practice, 2012, 208, 104-108.	1.0	30
160	Molecular cloning of novel alternatively spliced variants of BCL2L12, a new member of the BCL2 gene family, and their expression analysis in cancer cells. Gene, 2012, 505, 153-166.	1.0	30
161	Kallikrein-related peptidase 4 (KLK4) mRNA predicts short-term relapse in colorectal adenocarcinoma patients. Cancer Letters, 2013, 330, 106-112.	3.2	30
162	<i>KLK11</i> mRNA expression predicts poor disease-free and overall survival in colorectal adenocarcinoma patients. Biomarkers in Medicine, 2014, 8, 671-685.	0.6	30

#	Article	IF	CITATIONS
163	The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clinical Chemistry, 1999, 45, 1960-6.	1.5	30
164	Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Research, 2005, 25, 3123-33.	0.5	30
165	The role of human tissue kallikreins 7 and 8 in intracranial malignancies. Biological Chemistry, 2006, 387, 1607-1612.	1.2	29
166	Loss of miR-378 in prostate cancer, a common regulator of <i>KLK2</i> and <i>KLK4</i> , correlates with aggressive disease phenotype and predicts the short-term relapse of the patients. Biological Chemistry, 2014, 395, 1095-1104.	1.2	29
167	Prognostic and predictive biomarkers in prostate cancer. Expert Review of Molecular Diagnostics, 2015, 15, 1567-1576.	1.5	29
168	miR-10b is a prognostic marker in clear cell renal cell carcinoma. Journal of Clinical Pathology, 2017, 70, 854-859.	1.0	29
169	Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia. Leukemia Research, 2018, 70, 1-7.	0.4	29
170	Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients. Clinical Cancer Research, 2007, 13, 1742-1748.	3.2	28
171	Kallikreinâ€related peptidase 4 gene (<i>KLK4</i>) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance. Prostate, 2011, 71, 1780-1789.	1.2	28
172	Parallel overexpression and clinical significance of kallikrein-related peptidases 7 and 14 (KLK7 &) Tj ETQq0	0 0 rgBT /0 1.8	Overlock 10 T
173	High microRNA-28-5p expression in colorectal adenocarcinoma predicts short-term relapse of node-negative patients and poor overall survival of patients with non-metastatic disease. Clinical Chemistry and Laboratory Medicine, 2018, 56, 990-1000.	1.4	28
174	Circulating exosomal miRNAs: clinical significance in human cancers. Expert Review of Molecular Diagnostics, 2019, 19, 979-995.	1.5	28
175	Identification of a novel tRNAâ€derived RNA fragment exhibiting high prognostic potential in chronic lymphocytic leukemia. Hematological Oncology, 2019, 37, 498-504.	0.8	28
176	Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Research, 2007, 27, 3651-60.	0.5	28
177	Serum and Urinary Prostate-specific Antigen and Urinary Human Glandular Kallikrein Concentrations Are Significantly Increased after Testosterone Administration in Female-to-Male Transsexuals. Clinical Chemistry, 2000, 46, 859-862.	1.5	27
178	Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. Clinical Biochemistry, 2010, 43, 1205-1211.	0.8	27
179	Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis. Human Pathology, 2012, 43, 1037-1043.	1.1	27
180	Long Noncoding RNAs in Digestive System Malignancies: A Novel Class of Cancer Biomarkers and Therapeutic Targets?. Gastroenterology Research and Practice, 2015, 2015, 1-18.	0.7	27

#	Article	IF	CITATIONS
181	KLKB1 mRNA overexpression: A novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia. Clinical Biochemistry, 2015, 48, 849-854.	0.8	27
182	Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients. Clinical Cancer Research, 1999, 5, 1778-85.	3.2	27
183	Enhanced Antileukemic Activity of the Novel Complex 2,5-Dihydroxybenzoate Molybdenum(VI) against 2,5-Dihydroxybenzoate, Polyoxometalate of Mo(VI), and Tetraphenylphosphonium in the Human HL-60 and K562 Leukemic Cell Lines. Journal of Medicinal Chemistry, 2007, 50, 1316-1321.	2.9	26
184	Expression analysis and study of KLK4 in benign and malignant breast tumours. Thrombosis and Haemostasis, 2009, 101, 381-387.	1.8	26
185	Quantitative analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor. Tumor Biology, 2010, 31, 391-399.	0.8	26
186	A Comprehensive Phylogenetic and Structural Analysis of the Carcinoembryonic Antigen (CEA) Gene Family. Genome Biology and Evolution, 2014, 6, 1314-1326.	1.1	26
187	Identification of novel alternative splice variants of the BCL2L12 gene in human cancer cells using next-generation sequencing methodology. Cancer Letters, 2016, 373, 119-129.	3.2	26
188	mRNA overexpression of the hypoxia inducible factor 1 alpha subunit gene (HIF1A): An independent predictor of poor overall survival in chronic lymphocytic leukemia. Leukemia Research, 2017, 53, 65-73.	0.4	26
189	miRâ€221/222 cluster expression improves clinical stratification of nonâ€muscle invasive bladder cancer (TaT1) patients' risk for shortâ€term relapse and progression. Genes Chromosomes and Cancer, 2018, 57, 150-161.	1.5	26
190	Polyadenylate Polymerase (PAP) and 3' End pre-mRNA Processing: Function, Assays, and Association with Disease. Critical Reviews in Clinical Laboratory Sciences, 2002, 39, 193-224.	2.7	25
191	Kallikreins as Markers of Disseminated Tumour Cells in Ovarian Cancer – A Pilot Study. Tumor Biology, 2006, 27, 104-114.	0.8	25
192	Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. Annals of Oncology, 2008, 19, 1271-1277.	0.6	25
193	Pancreatic duct guidewire placement for biliary cannulation in a single-session therapeutic ERCP. World Journal of Gastroenterology, 2011, 17, 1989.	1.4	25
194	Quantitative expression analysis of the apoptosisâ€related gene, <i>BCL2L12</i> , in head and neck squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2013, 42, 154-161.	1.4	25
195	Targeting kallikrein-related peptidases in prostate cancer. Expert Opinion on Therapeutic Targets, 2014, 18, 365-383.	1.5	25
196	Profilin-1 expression is associated with high grade and stage and decreased disease-free survival in renal cell carcinoma. Human Pathology, 2015, 46, 673-680.	1.1	25
197	Copper(II) Inverse-[9-Metallacrown-3] Compounds Accommodating ÂNitrato or Diclofenac Ligands: Structure, Magnetism, and Biological Activity. European Journal of Inorganic Chemistry, 2016, 2016, 219-231.	1.0	25
198	miR-34a overexpression predicts poor prognostic outcome in colorectal adenocarcinoma, independently of clinicopathological factors with established prognostic value. Clinical Biochemistry, 2017, 50, 918-924.	0.8	25

#	Article	IF	CITATIONS
199	The miR-200 family as prognostic markers in clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 955-963.	0.8	25
200	Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer. Cancer Research, 2000, 60, 5427-33.	0.4	25
201	tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression. Cancers, 2022, 14, 24.	1.7	25
202	Prognostic value of kallikreinâ€related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). Cancer Science, 2008, 99, 2224-2229.	1.7	24
203	Trastuzumab plus Paclitaxel or Docetaxel in HER-2–Negative/HER-2 ECD–Positive Anthracycline- and Taxane-Refractory Advanced Breast Cancer. Oncologist, 2008, 13, 361-369.	1.9	24
204	Diagnostic and prognostic significance of human kallikrein 11 (KLK11) mRNA expression levels in patients with laryngeal cancer. Clinical Biochemistry, 2012, 45, 623-630.	0.8	24
205	Quantitative expression analysis and prognostic significance of the BCL2-associated Xgene in nasopharyngeal carcinoma: a retrospective cohort study. BMC Cancer, 2013, 13, 293.	1.1	24
206	Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity of <i>BCL-2</i> family gene members in stomach cancer cells. Cancer Biology and Therapy, 2013, 14, 587-596.	1.5	24
207	Kallikrein-related peptidase 6 (<i>KLK6</i>) expression in the progression of colon adenoma to carcinoma. Biological Chemistry, 2014, 395, 1105-1117.	1.2	24
208	Progression of mouse skin carcinogenesis is associated with the orchestrated deregulation of mirâ€200 family members, mirâ€205 and their common targets. Molecular Carcinogenesis, 2016, 55, 1229-1242.	1.3	24
209	Identification of a novel, internal tRNA-derived RNA fragment as a new prognostic and screening biomarker in chronic lymphocytic leukemia, using an innovative quantitative real-time PCR assay. Leukemia Research, 2019, 87, 106234.	0.4	24
210	Next generation sequencing targeted gene panel in Greek MODY patients increases diagnostic accuracy. Pediatric Diabetes, 2020, 21, 28-39.	1.2	24
211	Identification of Two Novel Circular RNAs Deriving from BCL2L12 and Investigation of Their Potential Value as a Molecular Signature in Colorectal Cancer. International Journal of Molecular Sciences, 2020, 21, 8867.	1.8	24
212	Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. Clinical Cancer Research, 1999, 5, 815-21.	3.2	24
213	Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol. Biological Chemistry, 2008, 389, 1427-1434.	1.2	23
214	Association between kallikrein-related peptidases (KLKs) and macroscopic indicators of semen analysis: their relation to sperm motility. Biological Chemistry, 2009, 390, 921-929.	1.2	23
215	Cathepsin B protein levels in endometrial cancer: Potential value as a tumour biomarker. Gynecologic Oncology, 2009, 112, 531-536.	0.6	23
216	High clusterin (CLU) mRNA expression levels in tumors of colorectal cancer patients predict a poor prognostic outcome. Clinical Biochemistry, 2020, 75, 62-69.	0.8	23

#	Article	IF	CITATIONS
217	A novel, mitochondrial, internal tRNA-derived RNA fragment possesses clinical utility as a molecular prognostic biomarker in chronic lymphocytic leukemia. Clinical Biochemistry, 2020, 85, 20-26.	0.8	23
218	Significance of Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor-1 (PAI-1) Expression in Human Colorectal Carcinomas. Tumor Biology, 2002, 23, 170-178.	0.8	22
219	Molecular characterization of a new gene, CEAL1, encoding for a carcinoembryonic antigen-like protein with a highly conserved domain of eukaryotic translation initiation factors. Gene, 2003, 310, 79-89.	1.0	22
220	Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions. Clinical Proteomics, 2011, 8, 5.	1.1	22
221	The single nucleotide polymorphism g.1548A >G (K469E) of the ICAM-1 gene is associated with worse prognosis in non-small cell lung cancer. Tumor Biology, 2012, 33, 1429-1436.	0.8	22
222	Cloning of a gene (SR-A1), encoding for a new member of the human Ser/Arg-rich family of pre-mRNA splicing factors: overexpression in aggressive ovarian cancer. British Journal of Cancer, 2001, 85, 190-198.	2.9	21
223	Quantitative Analysis of Human Kallikrein 5 (KLK5) Expression in Prostate Needle Biopsies: An Independent Cancer Biomarker. Clinical Chemistry, 2009, 55, 904-913.	1.5	21
224	Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact. Tumor Biology, 2012, 33, 1075-1084.	0.8	21
225	Blood-based analysis of type-2 diabetes mellitus susceptibility genes identifies specific transcript variants with deregulated expression and association with disease risk. Scientific Reports, 2019, 9, 1512.	1.6	21
226	Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thrombosis and Haemostasis, 2009, 101, 741-7.	1.8	21
227	Lâ€dopa decarboxylase (<i>DDC</i>) gene expression is related to outcome in patients with prostate cancer. BJU International, 2012, 110, E267-73.	1.3	20
228	Clinical utility of microRNAs in renal cell carcinoma: current evidence and future perspectives. Expert Review of Molecular Diagnostics, 2018, 18, 981-991.	1.5	20
229	Free/Total PSA (F/T ratio) kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomy. Clinica Chimica Acta, 2005, 357, 196-201.	0.5	19
230	Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biological Chemistry, 2006, 387, 1629-33.	1.2	19
231	mRNA expression analysis of human kallikrein 11 (KLK11) may be useful in the discrimination of benign prostatic hyperplasia from prostate cancer after needle prostate biopsy. Biological Chemistry, 2006, 387, 789-793.	1.2	19
232	Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. Thrombosis and Haemostasis, 2009, 101, 373-380.	1.8	19
233	Comparative study of balloon and metal olive dilators for endoscopic management of benign anastomotic rectal strictures: clinical and cost-effectiveness outcomes. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 756-763.	1.3	19
234	L-DOPA decarboxylase mRNA expression is associated with tumor stage and size in head and neck squamous cell carcinoma: a retrospective cohort study. BMC Cancer, 2012, 12, 484.	1.1	19

#	Article	IF	CITATIONS
235	Cytotoxic activity of sunitinib and everolimus in Caki-1 renal cancer cells is accompanied by modulations in the expression of apoptosis-related microRNA clusters and BCL2 family genes. Biomedicine and Pharmacotherapy, 2015, 70, 33-40.	2.5	19
236	Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thrombosis and Haemostasis, 2009, 101, 541-546.	1.8	19
237	Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter. Breast Cancer Research and Treatment, 2000, 61, 111-119.	1.1	18
238	Combined Expression of p53, Bcl-2, and p21WAF-1 Proteins in Lung Cancer and Premalignant Lesions: Association with Clinical Characteristics. Lung, 2001, 179, 265-278.	1.4	18
239	Molecular Response of HLâ€60 Cells to Mitotic Inhibitors Vincristine and Taxol Visualized with Apoptosisâ€Related Gene Expressions, Including the New Member <i>BCL2L12</i> . Annals of the New York Academy of Sciences, 2009, 1171, 276-283.	1.8	18
240	Expression analysis and study of the <i>KLK15</i> mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Cancer Science, 2010, 101, 693-699.	1.7	18
241	BCL2L12: A promising molecular prognostic biomarker in breast cancer. Clinical Biochemistry, 2014, 47, 257-262.	0.8	18
242	Clinical evaluation of microRNA-145 expression in renal cell carcinoma: a promising molecular marker for discriminating and staging the clear cell histological subtype. Biological Chemistry, 2016, 397, 529-539.	1.2	18
243	MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2019, 60, 658-667.	0.6	18
244	Discovery of novel transcripts of the human tissue kallikrein (KLK1) and kallikrein-related peptidase 2 (KLK2) in human cancer cells, exploiting Next-Generation Sequencing technology. Genomics, 2019, 111, 642-652.	1.3	18
245	Blood-based analysis of 84 microRNAs identifies molecules deregulated in individuals with type-2 diabetes, risk factors for the disease or metabolic syndrome. Diabetes Research and Clinical Practice, 2020, 164, 108187.	1.1	18
246	The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas. Biomedicines, 2021, 9, 333.	1.4	18
247	Novel splice variants of prostate-specific antigen and applications in diagnosis of prostate cancer. Clinical Biochemistry, 2008, 41, 591-597.	0.8	17
248	Synthesis, spectroscopic study and anticancer activity of a water-soluble Nb(V) peroxo complex. Journal of Inorganic Biochemistry, 2011, 105, 155-163.	1.5	17
249	Quantified <i>KLK15</i> Gene Expression Levels Discriminate Prostate Cancer From Benign Tumors and Constitute a Novel Independent Predictor of Disease Progression. Prostate, 2013, 73, 1191-1201.	1.2	17
250	Predictions for the future of kallikrein-related peptidases in molecular diagnostics. Expert Review of Molecular Diagnostics, 2014, 14, 713-722.	1.5	17
251	Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma. Clinical and Experimental Metastasis, 2015, 32, 531-541.	1.7	17
252	Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer. Tumor Biology, 2015, 36, 4979-4986.	0.8	17

#	Article	IF	CITATIONS
253	Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival. Breast Cancer Research and Treatment, 2015, 152, 323-336.	1.1	17
254	Identification and molecular cloning of novel transcripts of the human kallikrein-related peptidase 10 (KLK10) gene using next-generation sequencing. Biochemical and Biophysical Research Communications, 2017, 487, 776-781.	1.0	17
255	The transcriptome of a "sleeping―invader: de novo assembly and annotation of the transcriptome of aestivating Cornu aspersum. BMC Genomics, 2017, 18, 491.	1.2	17
256	Molecular cloning of novel transcripts of human kallikrein-related peptidases 5, 6, 7, 8 and 9 (KLK5 –) Tj ETQq(0 0 rgBT 1.6	/Oyerlock 10
257	Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis. Oncotarget, 2017, 8, 6896-6913.	0.8	17
258	Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia. Annals of Hematology, 2018, 97, 1169-1182.	0.8	17
259	HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study. PLoS ONE, 2019, 14, e0215984.	1.1	17
260	Heat shock protein beta 3 (HSPB3) is an unfavorable molecular biomarker in colorectal adenocarcinoma. Molecular Carcinogenesis, 2020, 59, 116-125.	1.3	17
261	Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background. International Journal of Molecular Sciences, 2021, 22, 2375.	1.8	17
262	Alternative Splicing Detection Tool—a novel PERL algorithm for sensitive detection of splicing events, based on next-generation sequencing data analysis. Annals of Translational Medicine, 2018, 6, 244-244.	0.7	17
263	Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients. Anticancer Research, 1993, 13, 1895-900.	0.5	17
264	Codon 89 polymorphism in the human 5 $\hat{I}\pm$ -reductase gene in primary breast cancer. British Journal of Cancer, 2001, 84, 760-767.	2.9	16
265	Treatment of Gastric Cancer Cells with 5-Fluorouracil/Leucovorin and Irinotecan Induces Distinct Alterations in the mRNA Expression of the Apoptosis-Related Genes, Including the Novel Gene <i>BCL2L12</i> . Tumor Biology, 2009, 30, 100-107.	0.8	16
266	KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone. Biological Chemistry, 2010, 391, 467-74.	1.2	16
267	l-DOPA Decarboxylase (DDC) Expression Status as a Novel Molecular Tumor Marker for Diagnostic and Prognostic Purposes in Laryngeal Cancer. Translational Oncology, 2012, 5, 288-296.	1.7	16
268	Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers. Medical Oncology, 2013, 30, 405.	1.2	16
269	The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine. Clinical Cancer Research, 2016, 22, 1958-1968.	3.2	16
270	Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 521-532.	1.2	16

#	Article	IF	CITATIONS
271	Expression Analysis of miR-29b in Malignant and Benign Breast Tumors: A Promising Prognostic Biomarker for Invasive Ductal Carcinoma With a Possible Histotype-Related Expression Status. Clinical Breast Cancer, 2018, 18, 305-312.e3.	1.1	16
272	Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. Thrombosis and Haemostasis, 2003, 89, 1081-8.	1.8	16
273	DRAMATIC SUPPRESSION OF PLASMA AND URINARY PROSTATE SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN BY ANTIANDROGENS IN MALE-TO-FEMALE TRANSSEXUALS. Journal of Urology, 2000, 163, 802-805.	0.2	15
274	Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors. Tumor Biology, 2012, 33, 1375-1383.	0.8	15
275	mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients. Clinical Chemistry and Laboratory Medicine, 2016, 54, 315-24.	1.4	15
276	Unravelling a p73-regulated network: The role of a novel p73-dependent target, MIR3158, in cancer cell migration and invasiveness. Cancer Letters, 2017, 388, 96-106.	3.2	15
277	Identification and Characterization of a Novel Human Testis-Specific Kinase Substrate Gene Which Is Downregulated in Testicular Tumors. Biochemical and Biophysical Research Communications, 2001, 285, 400-408.	1.0	14
278	Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer. Tumor Biology, 2012, 33, 1209-1214.	0.8	14
279	The role of transcription factors in laboratory medicine. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1563-1571.	1.4	14
280	Low mRNA expression levels of kallikrein-related peptidase 4 (<i>KLK4</i>) predict short-term relapse in patients with laryngeal squamous cell carcinoma. Biological Chemistry, 2014, 395, 1051-1062.	1.2	14
281	S100A11 is a potential prognostic marker for clear cell renal cell carcinoma. Clinical and Experimental Metastasis, 2016, 33, 63-71.	1.7	14
282	Novel alternative splice variants of the human protein arginine methyltransferase 1 (PRMT1) gene, discovered using next-generation sequencing. Gene, 2019, 699, 135-144.	1.0	14
283	Unraveling UCA1 IncRNA prognostic utility in urothelial bladder cancer. Carcinogenesis, 2019, 40, 965-974.	1.3	14
284	Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. Clinica Chimica Acta, 2000, 292, 127-138.	0.5	13
285	Effect of Testosterone Administration on Serum and Urine Kallikrein Concentrations in Female-to-Male Transsexuals. Clinical Chemistry, 2006, 52, 1546-1551.	1.5	13
286	Identification of a STAT5 Target Gene, Dpf3, Provides Novel Insights in Chronic Lymphocytic Leukemia. PLoS ONE, 2013, 8, e76155.	1.1	13
287	A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 13144.	1.8	13
288	Enhanced Concentration-Dependent Cytotoxic Effect of the Dinuclear Copper(II) Complex of <scp>l</scp> -Carnitine [Cu ₂ (<scp>l</scp> -carnitine) ₂ Cl ₂ (H ₂ O) ₂]Cl <s Compared to<scp>l</scp>-Carnitine or Copper Chloride Dihydrate, in Human Leukemic Cell Lines. Journal of Medicinal Chemistry, 2008, 51, 3713-3719.</s 	ub2:2 <td>b>12</td>	b>12

#	Article	IF	CITATIONS
289	Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients. Clinical and Experimental Medicine, 2018, 18, 203-213.	1.9	12
290	Unraveling novel survivin mRNA transcripts in cancer cells using an in-house developed targeted high-throughput sequencing approach. Genomics, 2021, 113, 573-581.	1.3	12
291	SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. Vaccines, 2021, 9, 207.	2.1	12
292	A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. Cancers, 2021, 13, 3877.	1.7	12
293	High Expression of a tRNAPro Derivative Associates with Poor Survival and Independently Predicts Colorectal Cancer Recurrence. Biomedicines, 2022, 10, 1120.	1.4	12
294	10-(2-Biotinyloxyethyl)-9-acridone. Journal of Photochemistry and Photobiology A: Chemistry, 2006, 181, 126-131.	2.0	11
295	Comparative HPLC-DAD and UHPLC-ESI(-)-HRMS & amp; MS/MS profiling of Hypericum species and correlation with necrotic cell-death activity in human leukemic cells. Phytochemistry Letters, 2017, 20, 481-490.	0.6	11
296	Human kallikrein-related peptidase 12 (KLK12) splice variants discriminate benign from cancerous breast tumors. Clinical Biochemistry, 2018, 58, 78-85.	0.8	11
297	A 3′ tRNAâ€derived fragment produced by tRNA LeuAAG and tRNA LeuTAG is associated with poor prognosis in Bâ€cell chronic lymphocytic leukemia, independently of classical prognostic factors. European Journal of Haematology, 2021, 106, 821-830.	1.1	11
298	Novel Nested-Seq Approach for SARS-CoV-2 Real-Time Epidemiology and In-Depth Mutational Profiling in Wastewater. International Journal of Molecular Sciences, 2021, 22, 8498.	1.8	11
299	miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. British Journal of Cancer, 2022, 126, 79-90.	2.9	11
300	Identification of Novel Circular RNAs of the Human Protein Arginine Methyltransferase 1 (PRMT1) Gene, Expressed in Breast Cancer Cells. Genes, 2022, 13, 1133.	1.0	11
301	Novel biotinylated acridinium derivatives: New reagents for fluorescence immunoassays and proteomics. Clinica Chimica Acta, 2005, 357, 159-167.	0.5	10
302	Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues. Thrombosis and Haemostasis, 2011, 105, 131-137.	1.8	10
303	Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia. Clinical Biochemistry, 2012, 45, 1362-1367.	0.8	10
304	The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents. Tumor Biology, 2012, 33, 2069-2078.	0.8	10
305	Increased BCL2L12 expression predicts the short-term relapse of patients with TaT1 bladder cancer following transurethral resection of bladder tumors. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 39.e29-39.e36.	0.8	10
306	Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse. Journal of Cancer Research and Clinical Oncology, 2015, 141, 2023-2036.	1.2	10

#	Article	IF	CITATIONS
307	Cisplatin and Paclitaxel Alter the Expression Pattern of miRâ€143/145 and miRâ€183/96/182 Clusters in T24 Bladder Cancer Cells. Clinical and Translational Science, 2015, 8, 668-675.	1.5	10
308	Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes. Tumor Biology, 2015, 36, 3197-3207.	0.8	10
309	BCL2L12: a multiply spliced gene with independent prognostic significance in breast cancer. Clinical Chemistry and Laboratory Medicine, 2018, 57, 276-287.	1.4	10
310	BCL2L12 improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia. Clinical Chemistry and Laboratory Medicine, 2018, 56, 2104-2118.	1.4	10
311	Novel splice variants of the human kallikrein-related peptidases 11 (<i>KLK11</i>) and 12 (<i>KLK12</i>), unraveled by next-generation sequencing technology. Biological Chemistry, 2018, 399, 1065-1071.	1.2	10
312	Kallikrein-related peptidases and associated microRNAs as promising prognostic biomarkers in gastrointestinal malignancies. Biological Chemistry, 2018, 399, 821-836.	1.2	10
313	Identification of novel alternative splice variants of the human L-DOPA decarboxylase (DDC) gene in human cancer cells, using high-throughput sequencing approaches. Gene, 2019, 719, 144075.	1.0	10
314	miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. Carcinogenesis, 2020, 41, 442-451.	1.3	10
315	Revised Exon Structure of I-DOPA Decarboxylase (DDC) Reveals Novel Splice Variants Associated with Colorectal Cancer Progression. International Journal of Molecular Sciences, 2020, 21, 8568.	1.8	10
316	Next-generation sequencing reveals alternative L-DOPA decarboxylase (DDC) splice variants bearing novel exons, in human hepatocellular and lung cancer cells. Gene, 2021, 768, 145262.	1.0	10
317	Quantitative analysis and study of the mRNA expression levels of apoptotic genes BCL2, BAX and BCL2L12 in the articular cartilage of an animal model of osteoarthritis. Annals of Translational Medicine, 2018, 6, 243-243.	0.7	10
318	Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?. Current Medicinal Chemistry, 2017, 24, 14-56.	1.2	10
319	Molecular Effects of Treatment of Human Colorectal Cancer Cells with Natural and Classical Chemotherapeutic Drugs: Alterations in the Expression of Apoptosis-related BCL2 Family Members, Including BCL2L12. Current Pharmaceutical Biotechnology, 2019, 19, 1064-1075.	0.9	10
320	Evidence for L-Dopa Decarboxylase Involvement in Cancer Cell Cytotoxicity Induced by Docetaxel and Mitoxantrone. Current Pharmaceutical Biotechnology, 2019, 19, 1087-1096.	0.9	10
321	Relationships between cathepsin-D, pS2 protein and hormonal receptors in breast cancer cytosols: inconsistency with their established prognostic significance. Anticancer Research, 1997, 17, 3665-9.	0.5	10
322	Expression analysis and study of KLK4 in benign and malignant breast tumours. Thrombosis and Haemostasis, 2009, 101, 381-7.	1.8	10
323	Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thrombosis and Haemostasis, 2009, 101, 541-6.	1.8	10
324	SR-A1, a member of the human pre-mRNA splicing factor family, and its expression in colon cancer progression. Biological Chemistry, 2004, 385, 785-90.	1.2	9

#	Article	IF	CITATIONS
325	Multidisciplinary Therapy of Locally Farâ€Advanced or Inflammatory Breast Cancer with Fixed Perioperative Sequence of Epirubicin, Vinorelbine, and Fluorouracil Chemotherapy, Surgery, and Radiotherapy: Longâ€Term Results. Oncologist, 2006, 11, 563-573.	1.9	9
326	BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era. Leukemia and Lymphoma, 2016, 57, 2199-2203.	0.6	9
327	Discovery and expression analysis of novel transcripts of the human SR-related CTD-associated factor 1 (SCAF1) gene in human cancer cells using Next-Generation Sequencing. Gene, 2018, 670, 155-165.	1.0	9
328	Molecular cloning of novel transcripts of the adaptor-related protein complex 2 alpha 1 subunit (AP2A1) gene, using Next-Generation Sequencing. Gene, 2018, 678, 55-64.	1.0	9
329	Uncovering the clinical impact of kallikrein-related peptidase 5 (<i>KLK5</i>) mRNA expression in the colorectal adenoma-carcinoma sequence. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1251-1260.	1.4	9
330	c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. Anticancer Research, 1995, 15, 1543-7.	0.5	9
331	Evaluation of kallikrein-related peptidase 5 expression and its significance for breast cancer patients: association with kallikrein-related peptidase 7 expression. Anticancer Research, 2011, 31, 3093-100.	0.5	9
332	Cloning, physical mapping and structural characterization of the human α A -adaptin gene. Gene, 2002, 289, 191-199.	1.0	8
333	Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer. Biochemical and Biophysical Research Communications, 2006, 344, 667-674.	1.0	8
334	l-Dopa decarboxylase (DDC) constitutes an emerging biomarker in predicting patients' survival with stomach adenocarcinomas. Journal of Cancer Research and Clinical Oncology, 2013, 139, 297-306.	1.2	8
335	L-DOPA decarboxylase mRNA levels provide high diagnostic accuracy and discrimination between clear cell and non-clear cell subtypes in renal cell carcinoma. Clinical Biochemistry, 2015, 48, 590-595.	0.8	8
336	A comprehensive clinicopathological evaluation of the differential expression of microRNA-331 in breast tumors and its diagnostic significance. Clinical Biochemistry, 2018, 60, 24-32.	0.8	8
337	Gene-Specific Intron Retention Serves as Molecular Signature that Distinguishes Melanoma from Non-Melanoma Cancer Cells in Greek Patients. International Journal of Molecular Sciences, 2019, 20, 937.	1.8	8
338	Pediatric Ependymoma: A Proteomics Perspective. Cancer Genomics and Proteomics, 2017, 14, 127-136.	1.0	8
339	tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature. Biomedicines, 2021, 9, 1811.	1.4	8
340	A versatile 5′ RACE-Seq methodology for the accurate identification of the 5′ termini of mRNAs. BMC Genomics, 2022, 23, 163.	1.2	8
341	Expression of the C-terminal domain of novel human SR-A1 protein: Interaction with the CTD domain of RNA polymerase II. Biochemical and Biophysical Research Communications, 2005, 334, 61-68.	1.0	7
342	The Immunohistochemical Expression of Growth Hormone-Releasing Hormone Receptor Splice Variant 1 Is a Favorable Prognostic Marker in Colorectal Cancer. Molecular Medicine, 2009, 15, 242-247.	1.9	7

#	Article	IF	CITATIONS
343	Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer. European Journal of Clinical Investigation, 2012, 42, 777-783.	1.7	7
344	Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate. Tumor Biology, 2013, 34, 369-378.	0.8	7
345	Contribution of miRNAs, tRNAs and tRFs to Aberrant Signaling and Translation Deregulation in Lung Cancer. Cancers, 2020, 12, 3056.	1.7	7
346	miR â€181a overexpression predicts the poor treatment response and earlyâ€progression of serous ovarian cancer patients. International Journal of Cancer, 2020, 147, 3560-3573.	2.3	7
347	Prognostic significance of the expression of SR-A1, encoding a novel SR-related CTD-associated factor, in breast cancer. Biological Chemistry, 2006, 387, 1613-8.	1.2	6
348	Total and free PSA kinetics in patients without prostate cancer undergoing radical cystoprostatectomy. Prostate, 2008, 68, 759-765.	1.2	6
349	Kallikreinâ€related peptidases (KLKs) as novel potential biomarkers in gastric cancer: An open yet challenging road lies ahead. Journal of Surgical Oncology, 2012, 105, 223-224.	0.8	6
350	Nanopore Sequencing Unveils Diverse Transcript Variants of the Epithelial Cell-Specific Transcription Factor Elf-3 in Human Malignancies. Genes, 2021, 12, 839.	1.0	6
351	Prostate-Specific Antigen and Human Glandular Kallikrein 2 Are Markedly Elevated in Urine of Patients with Polycystic Ovary Syndrome. , 0, .		6
352	Cathepsin D may help in discriminating node-negative breast cancer patients at risk for local-regional recurrence. Anticancer Research, 1998, 18, 2885-90.	0.5	6
353	TA repeat polymorphism of the 5alpha-reductase gene and breast cancer. Cancer Epidemiology Biomarkers and Prevention, 2000, 9, 387-93.	1.1	6
354	Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. Thrombosis and Haemostasis, 2009, 101, 373-80.	1.8	6
355	Safety and Efficacy of Trastuzumab Every 3 Weeks Combined with Cytotoxic Chemotherapy in Patients with HER2-Positive Recurrent Breast Cancer: Findings from a Case Series. Oncology Research and Treatment, 2005, 28, 558-564.	0.8	5
356	Serum and Urine Tissue Kallikrein Concentrations in Male-to-Female Transsexuals Treated with Antiandrogens and Estrogens. Clinical Chemistry, 2006, 52, 1356-1365.	1.5	5
357	Cathepsin D concentration in tumor cytosols improves the accuracy of prognostic evaluation of primary breast cancer. Anticancer Research, 1997, 17, 1405-9.	0.5	5
358	Overexpression of the GR Riborepressor LncRNA GAS5 Results in Poor Treatment Response and Early Relapse in Childhood B-ALL. Cancers, 2021, 13, 6064.	1.7	5
359	<scp>Epiâ€miRNAs</scp> : Modern mediators of methylation status in human cancers. Wiley Interdisciplinary Reviews RNA, 2023, 14, e1735.	3.2	5
360	The kallikreins: old proteases with new clinical potentials. Thrombosis and Haemostasis, 2013, 110, 396-398.	1.8	4

#	Article	IF	CITATIONS
361	Human l-DOPA decarboxylase mRNA is a target of miR-145: A prediction to validation workflow. Gene, 2015, 554, 174-180.	1.0	4
362	Expressional profiling and clinical relevance of RNase κ in prostate cancer: a novel indicator of favorable progression-free survival. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2049-2057.	1.2	4
363	ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3075-3087.	1.2	4
364	Complex transcriptional regulation of the BCL2L12 gene: Novel, active promoter in K562 cells. Gene, 2020, 750, 144723.	1.0	4
365	Molecular Biomarkers of Laryngeal Cancer Laryngeal squamous cell carcinoma (LSCC) Tumor markers. Biomarkers in Disease, 2015, , 891-919.	0.0	4
366	mRNA quantification and clinical evaluation of telomerase reverse transcriptase subunit (hTERT) in intracranial tumours of patients in the island of Crete. British Journal of Cancer, 2005, 93, 152-158.	2.9	3
367	DDC (dopa decarboxylase (aromatic L-amino acid decarboxylase)). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2012, , .	0.1	3
368	Editorial (Thematic Issue: The Effects of Anticancer Agents on Cell Apoptosis and on the Expression of) Tj ETQq0	0 0 rgBT /	Ovgrlock 10
369	Multianalyte quantitative competitive PCR on optically encoded microspheres for an eight-gene panel related to prostate cancer. Analytical and Bioanalytical Chemistry, 2018, 410, 971-980.	1.9	3
370	Identification of novel alternative transcripts of the human Ribonuclease κ (RNASEK) gene using 3′ RACE and high-throughput sequencing approaches. Genomics, 2020, 112, 943-951.	1.3	3
371	Identification and expression analysis of novel splice variants of the human carcinoembryonic antigen-related cell adhesion molecule 19 (CEACAM19) gene using a high-throughput sequencing approach. Genomics, 2020, 112, 4268-4276.	1.3	3
372	Jagged Ends of Cell-Free DNA: Rebranding Fragmentomics in Modern Liquid Biopsy Diagnostics. Clinical Chemistry, 2021, 67, 576-578.	1.5	3
373	Pharmacoepigenomics circuits induced by a novel retinoid-polyamine conjugate in human immortalized keratinocytes. Pharmacogenomics Journal, 2021, 21, 638-648.	0.9	3
374	Identification and expression analysis of ten novel small non-coding RNAs (sncRNAs) in cancer cells using a high-throughput sequencing approach. Gene, 2022, 809, 146025.	1.0	3
375	Poly(A)polymerase activity levels in breast tumour cytosols. Journal of Experimental and Clinical Cancer Research, 1998, 17, 511-8.	0.4	3
376	10 Kallikrein-related Peptidases as Biomarkers in Personalized Cancer Medicine. , 2012, , 201-218.		2
377	Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances. Anti-Cancer Drugs, 2013, 24, 291-299.	0.7	2
378	Kallikreins as Biomarkers in Human Malignancies. Biomarkers in Disease, 2015, , 135-165.	0.0	2

#	Article	IF	CITATIONS
379	Quantitative Analysis of Kallikrein 15 Gene Expression in Prostate Tissue. Journal of Urology, 2003, , 361-364.	0.2	2
380	Targeted Long-Read Sequencing Decodes the Transcriptional Atlas of the Founding RAS Gene Family Members. International Journal of Molecular Sciences, 2021, 22, 13298.	1.8	2
381	Effect of bleomycin and cisplatin on the expression profile of <i>SRA1</i> , a novel member of pre-mRNA splicing factors, in HL-60 human promyelocytic leukemia cells. Biological Chemistry, 2007, 388, 773-778.	1.2	1
382	Highlight: Kinin 2012 in Paris. Biological Chemistry, 2013, 393, 299-300.	1.2	1
383	THE tRNAâ€DERIVED RNA FRAGMENTS (tRFs) BEARING THE GLYCINE ANTICODONS GCC AND CCC AS EMERGING MOLECULAR BIOMARKERS OF UNFAVORABLE PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA. Hematological Oncology, 2019, 37, 375-376.	0.8	1
384	A comprehensive nanopore sequencing methodology deciphers the complete transcriptional landscape of cyclin dependent kinase 4 (CDK4) in human malignancies. FEBS Journal, 2021, , .	2.2	1
385	Molecular Biomarkers of Laryngeal Cancer. , 2014, , 1-24.		1
386	A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients. Blood, 2019, 134, 5528-5528.	0.6	1
387	Evaluation of the clinical utility of kallikrein-related peptidase 6 gene (KLK6) downregulation in breast cancer Journal of Clinical Oncology, 2012, 30, 10606-10606.	0.8	1
388	Kallikreins as Biomarkers in Human Malignancies. , 2014, , 1-25.		1
389	BCL2L12 (BCL2-like 12 (proline-rich)). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
390	SCAF1 (SR-related CTD-associated factor 1). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
391	Manfred Schmitt (1947–2018). Biological Chemistry, 2018, 399, 923-924.	1.2	0
392	The interplay between miR-1245a and BRCA2 in colorectal cancer. Annals of Translational Medicine, 2020, 8, 1043-1043.	0.7	0
393	Identification of six novel alternative transcripts of the human kallikrein-related peptidase 15 (KLK15), using 3′RACE and high-throughput sequencing. Gene, 2020, 749, 144708.	1.0	0
394	Association of BCL2L12 overexpression with prolonged disease-free survival in breast cancer Journal of Clinical Oncology, 2014, 32, e22202-e22202.	0.8	0
395	Steroid Hormone Regulation and Prognostic Value of the Human Kallikrein Gene 14 in Ovarian Cancer. American Journal of Clinical Pathology, 2003, 119, 0-0.	0.4	0
396	Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer. American Journal of Translational Research (discontinued), 2021, 13, 1594-1606.	0.0	0